Welcome to our dedicated page for Onconetix news (Ticker: ONCO), a resource for investors and traders seeking the latest updates and insights on Onconetix stock.
Onconetix, Inc. develops and commercializes biotechnology solutions for men's health and oncology, with Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union, as a core company-specific product. News about ONCO commonly centers on diagnostic commercialization, clinical or regulatory disclosures, operating and financial results, and material agreements tied to its biotechnology business.
Company updates also cover capital-structure actions, including preferred stock and warrant financings, shareholder votes, reverse stock splits, Nasdaq listing compliance matters, and board or executive governance changes.
Realbotix (TSX-V: XBOT) reported Q2-2026 revenue of $225,000 and six-month revenue of $578,000, down from $727,000 and $1,543,000 a year earlier, mainly from exiting crypto operations and reallocating capital to humanoid robotics.
Gross margin was -1.7% in Q2-2026 and 19.0% year-to-date, versus 48.6% and 45.9% previously. Operating expenses rose to $1.746 million in Q2 as hiring increased. Total comprehensive income was $442,375 in Q2 and a loss of $849,000 for six months, helped by one-time gains and no crypto revaluation losses.
Realbotix is advancing a reverse takeover listing of subsidiary Realbotix LLC on Nasdaq via Onconetix (NASDAQ: ONCO), targeted to close before October 31, 2026. The robotics AI team expanded from 8 to 20 FTEs, and deliveries, including to a large telecom client, are underway but not yet recognized as revenue.
Onconetix (NASDAQ: ONCO) announced a 1-for-10 reverse stock split, effective 12:01 a.m. ET on May 21, 2026. ONCO will continue trading on Nasdaq under the same symbol with new CUSIP 68237Q 401.
The split aims to meet Nasdaq’s $1.00 minimum bid price and will reduce outstanding shares from about 11.4 million to 1.14 million without changing authorized shares or proportional ownership, aside from cash-out of fractional shares.
Realbotix (TSX-V: XBOT) Subsidiary to List on Nasdaq via ONCO RTO
Realbotix plans to list its wholly owned subsidiary Realbotix LLC on the Nasdaq Capital Market through a reverse takeover of Onconetix (NASDAQ: ONCO), keeping a 75–90% stake. No new Parent Company shares or consolidation are required, and closing is targeted by October 2026.
Onconetix (Nasdaq: ONCO) reported Q1 2026 progress at subsidiary Proteomedix, developer of the Proclarix® blood test for clinically significant prostate cancer. Two new peer-reviewed publications from Danish studies support Proclarix® in reducing overdiagnosis and unnecessary biopsies and in predicting transition from active surveillance to treatment.
According to Onconetix, PMX also initiated the U.S. multi-center PRIME validation study with Labcorp, targeting up to 500 men, and expanded European use, including a UK screening initiative and a new collaboration partner in Turkey.
Onconetix (Nasdaq: ONCO) is acquiring Realbotix LLC in an all-stock share exchange and highlighted Realbotix's April 8, 2026 delivery of the first Vinci-equipped humanoid robot to Ericsson. Vinci is a patented AI vision system that recognizes returning users, recalls conversations, and tracks engagement for data collection.
The combined company is expected to trade on Nasdaq after closing, anticipated in the second half of 2026, subject to shareholder and regulatory approvals.
Onconetix (Nasdaq: ONCO) disclosed that Realbotix expects to deliver 19 previously ordered humanoid robots and related AI implementations across March, April, and May 2026 as it scales production capacity. Onconetix previously entered a definitive all-stock share exchange to acquire Realbotix LLC, with closing anticipated in 2H 2026, subject to shareholder and regulatory approvals. This update is provided for informational purposes and includes forward-looking statements; investors are cautioned against undue reliance.
Onconetix (Nasdaq: ONCO) announced leadership changes tied to a pending acquisition of Realbotix LLC on March 31, 2026. David White became CEO effective March 18, 2026; Sammy Dorf joined the Board and Audit Committee effective March 19, 2026. Karina Fedasz will remain Interim CFO.
The appointments are presented as strengthening governance and execution as the company advances a previously announced definitive agreement to acquire AI-powered humanoid robot developer Realbotix.
Onconetix (Nasdaq: ONCO) highlighted that Realbotix’s humanoid robot was featured as a live connected endpoint in Ericsson’s pre-standard 6G over-the-air trial at Ericsson’s U.S. headquarters in Plano, Texas on March 25, 2026. The robot streamed video and interacted in real time over Ericsson’s test network, demonstrating AI-agnostic integration across cloud and network environments. Onconetix reiterated its definitive share exchange agreement to acquire 100% of Realbotix LLC in an all-stock transaction announced February 12, 2026; closing and Nasdaq listing are expected in the second half of 2026, subject to shareholder and regulatory approvals.
Onconetix (NASDAQ: ONCO) announced a 1-for-5 reverse stock split effective 12:01 a.m. ET on March 25, 2026.
The Board set the ratio after stockholder approval on February 3, 2026; shares outstanding will fall from ~3.6 million to ~0.7 million to help meet Nasdaq's $1.00 minimum bid requirement.
Onconetix (Nasdaq: ONCO) will acquire Realbotix LLC in an all-stock share exchange that transfers 100% of Realbotix equity to Onconetix. The combined company expects to trade on Nasdaq and the deal is targeted to close in the second half of 2026.
Following closing, Realbotix Parent is expected to own between 75% and 90% of fully diluted common shares; Andrew Kiguel will become CEO of the combined company. Closing remains subject to shareholder and regulatory approvals in the US and Canada.